Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study.
Adherence and persistence with osteoporosis treatments are essential for reducing fracture risk. Once-daily teriparatide is available in Japan for treating osteoporosis in patients with a high risk of fracture. The study objective was to describe real-world adherence and persistence with once-daily teriparatide 20 μg during the first year of treatment for patients who started treatment during the first eight months of availability in Japan. This prescription database study involved patients with an index date (first claim) between October 2010 and May 2011, a preindex period ≥6 months, and a postindex period ≥12 months and who were aged >45 years. Adherence (medication possession ratio (MPR)) and persistence (time from the start of treatment to discontinuation; a 60-day gap in supply) were calculated. A total of 287 patients started treatment during the specified time period; 123 (42.9%) were eligible for inclusion. Overall mean (standard deviation) adherence was 0.702 (0.366), with 61.0% of patients having high adherence (MPR > 0.8). The percentage of patients remaining on treatment was 65.9% at 180 days and 61.0% at 365 days. Our findings suggest that real-world adherence and persistence with once-daily teriparatide in Japan are similar to that with once-daily teriparatide in other countries and with other osteoporosis medications.
Nagoya Rheumatology Clinic/Initiative for Rheumatology and Osteoporosis, Nagoya 4500002, Japan.
Ikuko
I
Tanaka
Lilly Research Laboratories Japan, Eli Lilly Japan K.K., 7-1-5 Isogami dori, Chuoku, Kobe 6510086, Japan.
Masayo
M
Sato
Statistical Programming, PharmaNet/i3 LLC, Indianapolis, IN 46280, USA.
Tomoko
T
Sugihara
Statistics, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Douglas E
DE
Faries
Surveillance & Epidemiology, Global Patient Safety Japan, Eli Lilly Japan K.K., Kobe 6510086, Japan.
Shuko
S
Nojiri
Global Health Outcomes, Eli Lilly Australia Pty Ltd, Sydney 2114, Australia.
Peita
P
Graham-Clarke
Lilly Research Laboratories Japan, Eli Lilly Japan K.K., 7-1-5 Isogami dori, Chuoku, Kobe 6510086, Japan.
Jennifer A
JA
Flynn
Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Russel T
RT
Burge